Coherus BioSci…
ProfileJobs (21)

Coherus BioSciences

Suggest Edit
    • Healthcarebioengineeringbiotechdrug development

    Coherus BioSciences is engaged in developing and commercializing biosimilar drugs of the highest quality and value. The Company’s product candidates include CHS-1701, drug pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma.

    Revenue(FY, 2017)
    $1.6 M
    Market capitalization(2018-10-15)
    $885.1 M
    TypePublic
    HQRedwood City, US
    Founded2010
    Size (employees)127 (est)-3%
    Websitecoherus.com
    Coherus BioSciences was founded in 2010 and is headquartered in Redwood City, US
    Report incorrect company information

    Viewing summary data as a guest

    Sign up for free to see all data

    Coherus BioSciences Office Locations

    Coherus BioSciences has an office in Redwood City
    Redwood City, US (HQ)
    600 333 Twin Dolphin Dr
    Show all (1)
    Report incorrect company information

    Coherus BioSciences Financials and Metrics

    Coherus BioSciences Revenue

    Coherus BioSciences's revenue was reported to be $1.56 m in FY, 2017
    USD

    Net income (Q2, 2018)

    		(88.0m)

    EBIT (Q2, 2018)

    		(86.9m)

    Market capitalization (15-Oct-2018)

    		885.1m

    Closing stock price (15-Oct-2018)

    		13.1

    Cash (30-Jun-2018)

    		130.0m
    Coherus BioSciences's current market capitalization is $885.1 m.
    Annual
    USDFY, 2014FY, 2015FY, 2016FY, 2017

    Revenue

    		31.1m30.0m190.1m1.6m

    Revenue growth, %

    		(3%)533%

    General and administrative expense

    		17.6m36.0m51.6m71.3m

    R&D expense

    		78.2m213.1m254.4m162.4m
    Quarterly
    USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

    Revenue

    		12.4m14.1m

    General and administrative expense

    		4.0m6.1m8.8m10.2m11.4m11.3m13.6m18.8m23.5m16.6m35.0m

    R&D expense

    		18.5m36.5m56.9m68.2m65.3m65.5m64.6m53.8m34.5m25.5m52.0m

    Operating expense total

    		22.5m42.6m65.8m78.4m76.7m76.8m78.2m72.6m58.0m42.0m86.9m
    show all
    Annual
    USDFY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		150.4m158.2m124.9m126.9m

    Inventories

    		1.9m

    Current Assets

    		179.1m197.4m161.5m145.5m

    PP&E

    		4.5m10.5m10.8m12.8m
    Quarterly
    USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

    Cash

    		100.9m115.1m206.1m153.7m179.6m220.9m159.7m124.9m73.4m82.0m130.0m

    Current Assets

    		118.9m143.9m239.6m189.3m211.6m236.8m177.3m208.3m153.3m112.2m172.8m

    PP&E

    		3.7m5.1m6.3m8.7m10.3m9.9m10.7m14.9m14.5m11.9m11.2m

    Goodwill

    		943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k943.0k
    show all
    Annual
    USDFY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(87.2m)(223.9m)(127.8m)(238.3m)

    Depreciation and Amortization

    		674.0k3.0m3.4m

    Accounts Payable

    		3.6m(5.0m)(3.8m)

    Cash From Operating Activities

    		(23.9m)(252.5m)(200.3m)
    Quarterly
    USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

    Net Income

    		(7.9m)(40.8m)(99.9m)(171.4m)(65.5m)(135.7m)(51.8m)(74.8m)(130.2m)(44.3m)(88.0m)

    Depreciation and Amortization

    		632.0k1.3m717.0k1.4m2.2m865.0k1.7m922.0k1.8m

    Accounts Payable

    		4.4m10.9m7.1m19.1m(6.8m)(7.4m)(1.6m)(7.3m)(3.8m)(1.1m)(2.3m)

    Cash From Operating Activities

    		(53.9m)(113.6m)(76.3m)(103.7m)(165.7m)(73.3m)(128.9m)(33.6m)(69.1m)
    show all
    USDY, 2018

    Financial Leverage

    		3 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    Generation Bio
    Healthcare - Private
    Casma Therapeutics
    Healthcare - Private
    Rallybio
    Healthcare - Private
    HepaRegeniX
    Healthcare - Private
    Compare competitors

    Coherus BioSciences Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Coherus BioSciences News and Updates

    September 25, 2018

    Coherus BioSciences Receives European Commission Approval for UDENYCA™ (Pegfilgrastim Biosimilar)

    REDWOOD CITY, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the European Commission (EC) has granted marketing authorization to UDENYCA™ (formerly CHS-1701), a pegfilgrastim (Neulasta®) biosimilar. UDENYCA™ is one of the first pegfilgrastim bi…
    August 17, 2018

    Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective August 14, 2018, the company’s board of directors granted 3 new employees options to purchase an aggregate of 35,500 shares of the company’s common stock with a per shar…
    August 08, 2018

    Coherus BioSciences Reports Corporate Highlights and Second Quarter 2018 Financial Results

    REDWOOD CITY, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended June 30, 2018.  
    July 27, 2018

    Coherus BioSciences Receives Positive CHMP Opinion for UDENYCA™ (Pegfilgrastim Biosimilar Candidate)

    REDWOOD CITY, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of UDENYCA™ (formerly CHS…
    May 10, 2018

    Coherus BioSciences' (CHRS) CEO Dennis Lanfear on Q1 2018 Results - Earnings Call Transcript

    Report incorrect company information

    Coherus BioSciences Company Life and Culture

    Report incorrect company information
    Download PDF